OncoMatch/Clinical Trials/NCT05753566
Rezvilutamide in Patients With Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
Is NCT05753566 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Rezvilutamide and Androgen deprivation therapy (ADT) for prostate cancer.
Treatment: Rezvilutamide · Androgen deprivation therapy (ADT) — To evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy(ADT) and standard salvage radiation therapy(SRT) or rezvilutamide in combination with ADT in prostate cancer patients with biochemical recurrence of prostate-specific antigen(PSA) persistence after radical prostatectomy(RP).
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: radical prostatectomy
radical prostatectomy
Cannot have received: hormonal therapy (antiandrogens, gonadotropin releasing hormone)
Prior hormonal therapy (antiandrogens or gonadotropin releasing hormone)
Cannot have received: radiation therapy
prior radiotherapy to pelvic
Lab requirements
Blood counts
ANC ≥ 1.5 x 10^9/L; Platelet count ≥ 100 x 10^9/L; Haemoglobin ≥ 90 g/L
Kidney function
Serum creatinine ≤ 1.5 x ULN or creatinine clearance > 50 ml/min
Liver function
Total bilirubin ≤ 1.5 x ULN; AST/SGOT or ALT/SGPT ≤ 2.5 x ULN
Cardiac function
LVEF ≥ 50%
Adequate laboratory parameters: ANC ≥ 1.5 x 10^9/L; Platelet count ≥ 100 x 10^9/L; Haemoglobin ≥ 90 g/L; Serum creatinine ≤ 1.5 x ULN or creatinine clearance > 50 ml/min; Total bilirubin ≤ 1.5 x ULN; AST/SGOT or ALT/SGPT ≤ 2.5 x ULN; INR ≤1.5, PT and APTT ≤1.5 x ULN; LVEF ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify